Cancer chemotherapy--what have we achieved?

Area of Science:

• Medical Oncology
• Clinical Outcomes Research
• Cancer Treatment Efficacy

Background:

• Evaluation of patient outcomes referred to a university teaching hospital's medical oncology unit in 1978.
• Analysis of demographic and diagnostic data for the first 500 patients.
• Comparison of cancer type distribution with broader regional statistics.

Purpose of the Study:

• To determine the outcomes of patients referred to a medical oncology unit.
• To assess the effectiveness and complications of cancer chemotherapy.
• To evaluate the cost-effectiveness of cytotoxic drug use.

Main Methods:

• Retrospective analysis of 500 consecutive patients seen in 1978.
• Data collection on patient demographics, diagnoses, treatments received, and survival.
• Comparison of survival rates between treated and untreated groups, and those receiving specific chemotherapy regimens.

Main Results:

• Median patient age was 58 years; 50% were referred within 6 weeks of diagnosis.
• Lung, breast, head and neck, ovarian, and testicular cancers were overrepresented; gastrointestinal cancers were underrepresented.
• No treatment was recommended for one-third of patients. Of those treated, 247 received cytotoxic drugs.
• 56% of treated and 52% of untreated patients died by August 1979; median survival was 45 weeks (treated) vs. 35 weeks (untreated).
• Only 17 of 50 patients receiving "curative" or "adjuvant" chemotherapy died by August 1979.
• Serious complications occurred in 8.8% of patients. Cytotoxic drugs cost A$212,000 (9.3% of pharmacy budget).

Conclusions:

• The study indicates that the broad application of cancer chemotherapy may not be warranted outside of rigorously designed clinical trials or dedicated cancer centers.
• Findings highlight the need for careful patient selection and evaluation of treatment protocols in medical oncology.
• The cost and complication rates associated with chemotherapy necessitate a critical assessment of its role in cancer management.